State Street Corp Belite Bio, Inc Put Options Transaction History
State Street Corp
- $2.21 Trillion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding BLTE
# of Institutions
12Shares Held
58.3KCall Options Held
0Put Options Held
0-
Marshall Wace, LLP London, X010.6KShares$481,5720.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.7KShares$395,8500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$304,8500.0% of portfolio
-
Morgan Stanley New York, NY6.09KShares$277,0950.0% of portfolio
-
Cubist Systematic Strategies, LLC Stamford, CT4.79KShares$217,8540.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.13B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...